Masahiro Hatori

Shizuoka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study.

Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study.

Journal: Investigational new drugs

Published: June 26, 2026

Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study.

Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study.

Journal: British journal of clinical pharmacology

Published: January 27, 2026

Factors Associated With Nonadherence to S-1 in Docetaxel+S-1(DS) Therapy, an Adjuvant Treatment for Gastric Cancer.

Factors Associated With Nonadherence to S-1 in Docetaxel+S-1(DS) Therapy, an Adjuvant Treatment for Gastric Cancer.

Journal: Anticancer research

Published: January 23, 2026

Nudge-based patient education by pharmacists to promote self-care behaviors for preventing and mitigating chemotherapy-induced skin toxicity: rationale, design, and study protocol of the PHARM-NUDGE trial.

Nudge-based patient education by pharmacists to promote self-care behaviors for preventing and mitigating chemotherapy-induced skin toxicity: rationale, design, and study protocol of the PHARM-NUDGE trial.

Journal: Journal of pharmaceutical health care and sciences

Published: November 27, 2025

Antiemetic Efficacy of Dexamethasone Omission in Antiemetic Therapy During Highly Emetogenic Chemotherapy for Breast Cancer.

Antiemetic Efficacy of Dexamethasone Omission in Antiemetic Therapy During Highly Emetogenic Chemotherapy for Breast Cancer.

Journal: Die Pharmazie

Published: November 11, 2025

Usefulness of pharmacy outpatient clinic follow-up for maintaining relative dose intensity in patients on adjuvant CAPOX chemotherapy for gastric cancer.

Usefulness of pharmacy outpatient clinic follow-up for maintaining relative dose intensity in patients on adjuvant CAPOX chemotherapy for gastric cancer.

Journal: Molecular and clinical oncology

Published: July 09, 2025

Impact of Comorbidity on Antiemetic Efficacy in Patients with Esophageal Cancer Treated with Cisplatin-Based Chemotherapy: A Retrospective Study from Japan.

Impact of Comorbidity on Antiemetic Efficacy in Patients with Esophageal Cancer Treated with Cisplatin-Based Chemotherapy: A Retrospective Study from Japan.

Journal: Oncology

Published: April 22, 2025

Comparing the Efficacy of a Triplet Antiemetic Regimen in Patients with Esophageal Cancer and Diabetes Mellitus Treated with Cisplatin-Based Chemotherapy: A Retrospective Study.

Comparing the Efficacy of a Triplet Antiemetic Regimen in Patients with Esophageal Cancer and Diabetes Mellitus Treated with Cisplatin-Based Chemotherapy: A Retrospective Study.

Journal: Oncology

Published: October 04, 2024

Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).

Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).

Journal: Cancer

Published: February 13, 2024

Evaluation of the Leftover Capecitabine Tablets in Adjuvant CAPOX Chemotherapy for Gastric Cancer

Evaluation of the Leftover Capecitabine Tablets in Adjuvant CAPOX Chemotherapy for Gastric Cancer

Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

Published: December 03, 2023

A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I.

A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I.

Journal: Investigational new drugs

Published: October 17, 2023

Influence of menopause on chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study.

Influence of menopause on chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study.

Journal: Cancer medicine

Published: February 03, 2023

Showing 1-12 of 15

Last Updated: 09/26/2026